Skip to content

Released Nov 13, 2024, after the close

10-Q filed Nov 13, 2024, 44 days after period end · 0000950170-24-126407

Q3 2024 · 10-Q
Revenue$8.52M−49.7% vs Q3 2023−66.9% vs Q2 2024
Net Income-$48.79MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.59N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$67,919,000N/M
Operating Cash Flowderived-$64,516,000N/M
Margins · derived
Operating margin-797.2%−537.1 pt vs Q3 2023
Net margin-572.6%−281.4 pt vs Q3 2023

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$8.52M$16.92M$25.15M$8.52M
Net Income-$48.79M-$49.28M-$19.49M-$30.90M
EPS Diluted-$0.59-$0.81-$0.37-$0.67

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR